



HEPREGEN CORPORATION EXPANDS AGREEMENT WITH BOEHRINGER INGELHEIM FOR THE ADOPTION OF HepatoPac™

*Technology Platform Provides Pharmaceutical Partners with Solution to
Improve Safety and Efficacy of Drugs for Better Patient Outcomes*

Medford, MA, January 6, 2011 – Hepregen Corporation, a leading provider of bioengineered solutions to improve patient outcomes, announced today that it has extended and expanded its agreement with Boehringer Ingelheim Pharmaceuticals, Inc. for the adoption of its proprietary technology platform, HepatoPac.

The expansion results from collaborative efforts the two companies began in 2009 aimed at evaluating HepatoPac for ADME/Tox applications. Under the terms of the new agreement, Hepregen will work with Boehringer Ingelheim Pharmaceuticals, Inc. to integrate HepatoPac into drug discovery and development programs.

Liver liabilities are one of the leading causes of preclinical failures of compounds in development, delays and failures of drugs in the clinic as well as post-market drug withdrawals. The pharmaceutical industry has lacked the availability of a sensitive and highly predictive liver model to help prioritize, select, and develop the safest candidates for clinical development. Earlier this year Hepregen commercialized HepatoPac, a microliver platform that is a long term, highly functional *in vitro* model of the liver. HepatoPac is currently being used by more than a dozen pharmaceutical partners in order to better prioritize and select drug candidates as they advance in the preclinical pipeline.

Bernadette C. (Bonnie) Fendrock, President and CEO of Hepregen commented on the agreement, “Boehringer Ingelheim has been a visionary partner in evaluating the performance of HepatoPac in multiple applications in order to obtain more sensitive and comprehensive information about the metabolism and safety of drug candidates before entering the clinic.”

“The extension of our agreement with Boehringer Ingelheim is a key milestone for Hepregen that validates the technical performance and commercial promise for HepatoPac. Hepregen’s mission is to provide bioengineered solutions that make a positive impact on drug development. In partnering with our customers, our goal is to help them provide the safest drugs to patients,” Fendrock added.

About Hepregen Corporation

Hepregen’s mission is to translate the value of its technology platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients’ lives. The company is focused on advancing and commercializing its microliver platform, HepatoPaC™, into the drug-development pipeline of pharmaceutical and biotechnology companies. Hepregen’s platform technology offers the potential to deliver a breakthrough technology for toxicity screening and a new platform for drug discovery. It combines sophisticated biological and engineering technologies to create an *in vitro* liver model which closely mimics many key functions and features of the human liver. In 2008, Battelle Ventures spun out Hepregen Corporation from the Massachusetts Institute of Technology (MIT), and led the company’s Series A financing. For more information about Hepregen, please visit: <http://www.hepregen.com/>

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of US \$17.7 billion (12.7 billion euro) while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit <http://us.boehringer-ingelheim.com> and follow us on Twitter at <http://twitter.com/boehringerus>.

###

Media Contact:

Amanda Murphy

LaVoie Group

Office: 978-745-4200 x107

amurphy@lavoiegroup.com

<http://www.lavoiegroup.com>